[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
November 1986

Growth Inhibition of Laryngeal UM-SCC Cell Lines by Tamoxifen: Comparison With Effects on the MCF-7 Breast Cancer Cell Line

Author Affiliations

From the Cancer Research Laboratory, Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor. Dr Shapira is now with the Department of Otolaryngology, Kaplan Hospital, Rehovot, Israel; Dr Virolainen is now with the Department of Otolaryngology, University of Turku (Finland) Central Hospital; Dr Jameson is now with the Department of Otolaryngology, Tufts University Medical Center, Boston; and Dr Ossakow is now with the Department of Otolaryngology, University of Miami.

Arch Otolaryngol Head Neck Surg. 1986;112(11):1151-1158. doi:10.1001/archotol.1986.03780110027002

• Six laryngeal squamous cell carcinoma (SCC) cell lines and the MCF-7 breast cancer line, all of which contain estrogen and progesterone receptors, were tested for in vitro growth inhibition by the antiestrogen tamoxifen citrate. Cell line MCF-7 was more sensitive to growth retardation at 1 μmol/L of tamoxifen citrate, but SCC lines showed higher sensitivity than MCF-7 to cytotoxic effects at higher drug concentrations (7 to 10 μmol/L). A cytostatic level of growth inhibition was produced by 5 μmol/L tamoxifen citrate for both types of cell lines. When tamoxifen and estradiol were added to cultures simultaneously, partial reversal of growth inhibition was observed with MCF-7 but not with UM-SCC-5. All of the cell lines recovered from inhibition when tamoxifen was replaced with 0.1 μmol/L estradiol, but laryngeal SCC lines recovered equally well in estradiol-free medium, whereas MCF-7 recovered only partially in the absence of estradiol. These findings indicate that there are at least two tamoxifen receptor sites—one for which estradiol is a competitor and one for which it is not—and that tamoxifen reversibly blocks growth and may synchronize SCC cells.

(Arch Otolaryngol Head Neck Surg 1986;112:1151-1158)